Arrowhead’s Finishes Enrolment for CALAA-01 Phase 1b Trial on Solid Tumors

Arrowhead Research Corporation, a specified therapeutics company, introduced that, by its Calando Pharmaceuticals part, it has finished joining of a phase 1b clinical trial of CALAA-01, its RNAi therapeutic applicant targeting solid tumors. All affected individuals joining with the trial have finished dosing except for one affected person who is still obtaining therapy and will always be watched. An exploration of final survey data has been prepared.

The phase 1b trial is definitely an open-label, dose-escalating study of the security of intravenously applied CALAA-01 in adults along with solid tumors refractory to standard-of-care alternatives. CALAA-01 is a mixture of the RONDEL delivery system as well as an unproved siRNA targeting the M2 subunit of ribonucleotide reductase (RRM2), a medically validated cancer targeted.

"We wish to take this chance to thank the affected individuals and physicians that made this trial possible," said Bruce D. Given, M.D., COO and head of R&D for Arrowhead. “Now that the CALAA-01 trial is finished, we could finalize and analyze the data for preview at a future investigation meeting."

Tiotropium Enhances Lung Function in Asthma Individuals

Data from the PrimoTinA-asthmaTM Phase III research studies presented for the very first time today with the 2012 European Respiratory Society (ERS) congress illustrate that tiotropium significantly lowered asthma exacerbations in affected individuals who remain characteristic despite therapy which have at the very least ICS/LABA.

Tiotropium also substantially enhanced lung function in characteristic asthma patients on ICS/LABA.

Professor Huib A M Kerstjens of the University Medical Centre, Groningen, The Netherlands, and lead author on both studies, said: "Each of these results surpassed our predictions. While we were waiting enhancements in lung function when introducing tiotropium to traditional care, the numerous lowering of the risk of exacerbations came being a surprise - especially given that each one affected individuals were usually already receiving optimal preservation therapy as described by the GINA guidelines."

There were also large enhancements in asthma control and asthma associated standard living (evaluated by the questionnaires ACQ and AQLQ) in one trial, as well as trends towards development in asthma manage in the other trial.

Despite current methods of treatment, there is an unmet medical need in asthma, as a significant proportion of affected individuals remains symptomatic and may possibly experience asthma exacerbations.